As interesting as it can be for patients with MS who hear about work being done to find the causes of multiple sclerosis, what we really want to see is research that is carried out to find a cure. Nothing more, nothing less. Of course, the development of new treatments is important, but the cure is what we need.
And while it is good that a new study has investigated the relationship between obesity and MS, and found what researchers described as a causal role, the results can only benefit people who haven’t got MS yet. It does nothing for people who live with this invited and unwanted guest. We just want a way to evict it.
The news that a new therapeutic vaccine was under the judgment also came out this week, but that resulted in a telling question in our comments section: “AGAIN, why has PPMS been excluded from the trial?” asked Steve John.
Well, no doubt the researchers had very good reasons, and on this individual point, I am not taking sides. However, in general, patients with PPMs tend to feel hard by, because, as of right now, there are no medications approved to treat this type of the disease.
A first for PPMS?
OK, now we have a drug that could become the first approved for primary progressive MS treatment. Our news story on the subject explained:
The U.S. Food and Drug Administration (FDA) is giving priority review to a request to approve Ocrevus (ocrelizumab) as a treatment for both forms of multiple sclerosis, the drug’s developer, Genentech, announced. If the company’s Biologics License Application (BLA) is approved, Ocrevus will become the first drug able to treat patients with either relapsing or primary progressive MS.
By designating the review a priority, the FDA will make its decision within six months rather than the standard 10, and release that decision on Dec. 28. Approval means the drug will be available for patients in the U.S.
If it is approved in the United States, the drug will soon be subject to review in Europe.
But we cannot please everyone all the time, and some simply don’t want to know about any medications. They are more afraid of possible side effects.
One of the comments I saw in an MS group on Facebook, in response to the news of ocrelizumab, was: “Another poison of the large pharmaceutical companies.” And, although I agree with concerns about side effects, the situation is that we may be able to go from the absence of any medicine to one that has been approved.
That said, some of us may prefer to follow the path of HSCT. Did you believe that it was purely for Relapsing MS? If so, you really need to rethink that.
Note: Multiple Sclerosis News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. The opinions expressed in this blog article are not those of Multiple Sclerosis News Today, or its parent company, BioNews Services, and are intended to spark discussion about issues pertaining to Multiple Sclerosis.